ABSTRACT
Objective To observe the effect of montelukast combined with budesonide on FEV1%, symptom score and adverse reaction in moderate to severe bronchial asthma patients. Methods 70 patients with moderate to severe bronchial asthma from April 2016 to April 2017 were randomly divided into single group and combined group. 35 patients in a single group were treated with budesonide, combined group 35 patients were treated with montelukast combined with budesonide, and the therapeutic effects were compared between the two groups after treatment. Results There were no differences in the scores of lung function and symptoms between two groups before treatment, and there was no significant difference in the incidence of adverse reactions between the two groups. After treatment, the lung function index, symptom score and total effective treatment of the combined group were obvious better than that of the single group (P<0.05). Conclusion Montelukast combined with budesonide in the treatment of moderate to severe bronchial asthma has good effect and high safety. It reduces the number of asthma attacks and improves the lung function of patients. It is worthy to be widely used and widely used in clinical practice.
ABSTRACT
Objective To observe the effect of montelukast combined with budesonide on FEV1%, symptom score and adverse reaction in moderate to severe bronchial asthma patients. Methods 70 patients with moderate to severe bronchial asthma from April 2016 to April 2017 were randomly divided into single group and combined group. 35 patients in a single group were treated with budesonide, combined group 35 patients were treated with montelukast combined with budesonide, and the therapeutic effects were compared between the two groups after treatment. Results There were no differences in the scores of lung function and symptoms between two groups before treatment, and there was no significant difference in the incidence of adverse reactions between the two groups. After treatment, the lung function index, symptom score and total effective treatment of the combined group were obvious better than that of the single group (P<0.05). Conclusion Montelukast combined with budesonide in the treatment of moderate to severe bronchial asthma has good effect and high safety. It reduces the number of asthma attacks and improves the lung function of patients. It is worthy to be widely used and widely used in clinical practice.
ABSTRACT
A novel chitinolytic and chitosanolytic bacterium, Sphingomonas sp. CJ-5, has been isolated and characterized. It secretes both chitinase and chitosanase into surrounding medium in response to chitin or chitosan induction. To characterize the enzymes, both chitinase and chitosanase were purified by ammonium sulfate precipitation, Sephadex G-200 gel filtration and DEAE-Sepharose Fast Flow. SDS-PAGE analysis demonstrated molecular masses of chitinase and chitosanase were 230 kDa and 45 kDa respectively. The optimum hydrolysis conditions for chitinase were about pH 7.0 and 36 degrees C, and these for chitosanase were pH 6.5 and 56 degrees C, respectively. Both enzymes were quite stable up to 45 degrees C for one hour at pH 5~8. These results show that CJ-5 may have potential for industrial application particularly in recycling of chitin wastes.